EGFR and non-small cell lung carcinoma: The ADAURA trial demonstrated that osimertinib, a third-generation EGFR-TKI, regardless of the use of adjuvant standard chemotherapy, significantly improved DFS with tolerable toxicity in patients with fully resected EGFR mutant NSCLC [14].